AMICUS THERAPEUTICS, INC. — Director's Dealing 2021

Oct 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-10-15

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-15	Common Stock	M	22000	$4.38	Acquired	854345	Direct
2021-10-15	Common Stock	S	22000	$11.2214	Disposed	832345	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-15	Stock Options (right to buy)	$4.38	M	22000	Disposed	2022-06-04	Common Stock (22000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.09 to $11.52 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of these options were fully vested and exercisable as of the transaction date.